These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21300657)

  • 1. Impact of the American Heart Association scientific statement on screening electrocardiograms and stimulant medications.
    Thomas PE; Carlo WF; Decker JA; Cannon BC; Kertesz NJ; Friedman RA; Kim JJ
    Arch Pediatr Adolesc Med; 2011 Feb; 165(2):166-70. PubMed ID: 21300657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular risk screening before starting stimulant medications and prescribing practices of canadian physicians: impact of the Health Canada advisory.
    Conway J; Wong KK; O'Connell C; Warren AE
    Pediatrics; 2008 Oct; 122(4):e828-34. PubMed ID: 18829780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. . . . and recommending an ECG starting stimulant medicines in kids.
    Child Health Alert; 2008 Sep; 26():2-3. PubMed ID: 18953696
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing.
    Vetter VL; Elia J; Erickson C; Berger S; Blum N; Uzark K; Webb CL; ;
    Circulation; 2008 May; 117(18):2407-23. PubMed ID: 18427125
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands.
    Sasané R; Hodgkins P; Meijer W
    Curr Med Res Opin; 2010 Nov; 26(11):2565-74. PubMed ID: 20863165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central stimulants in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents. A naturalistic study of the prescription in Sweden, 1977-2007.
    Janols LO; Liliemark J; Klintberg K; von Knorring AL
    Nord J Psychiatry; 2009 Nov; 63(6):508-16. PubMed ID: 19958258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The rise and fall of ADHD child prescribing in Western Australia: lessons and implications.
    Whitely M
    Aust N Z J Psychiatry; 2012 May; 46(5):400-3. PubMed ID: 22535289
    [No Abstract]   [Full Text] [Related]  

  • 8. Managing attention-deficit/hyperactivity disorder in primary care: a systematic analysis of roles and challenges.
    Power TJ; Mautone JA; Manz PH; Frye L; Blum NJ
    Pediatrics; 2008 Jan; 121(1):e65-72. PubMed ID: 18166546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drugged-out toddlers. A new study documents an alarming increase in behavior-altering medication for preschoolers.
    Kalb C
    Newsweek; 2000 Mar; 135(10):53. PubMed ID: 10847892
    [No Abstract]   [Full Text] [Related]  

  • 10. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular safety of medication treatments for attention-deficit/hyperactivity disorder.
    Newcorn JH; Donnelly C
    Mt Sinai J Med; 2009 Apr; 76(2):198-203. PubMed ID: 19306385
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.
    Christensen L; Sasané R; Hodgkins P; Harley C; Tetali S
    Curr Med Res Opin; 2010 Apr; 26(4):977-89. PubMed ID: 20178404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in medications administered in schools.
    McCarthy AM; Kelly MW; Johnson S; Roman J; Zimmerman MB
    J Sch Nurs; 2006 Apr; 22(2):102-7. PubMed ID: 16563033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Winterstein AG; Gerhard T; Shuster J; Johnson M; Zito JM; Saidi A
    Pediatrics; 2007 Dec; 120(6):e1494-501. PubMed ID: 18055666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and management of sudden death in children.
    Fish FA; Kannankeril PJ
    Curr Opin Pediatr; 2012 Oct; 24(5):592-602. PubMed ID: 22954955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulant medications and attention deficit-hyperactivity disorder.
    Cohen AL; Jhung MA; Budnitz DS
    N Engl J Med; 2006 May; 354(21):2294-5. PubMed ID: 16723627
    [No Abstract]   [Full Text] [Related]  

  • 17. ECGs before stimulants in children.
    Med Lett Drugs Ther; 2008 Jul; 50(1291):60. PubMed ID: 18654112
    [No Abstract]   [Full Text] [Related]  

  • 18. Primary care providers often first line of ADHD treatment.
    Mitchell L
    J Okla State Med Assoc; 2009 Nov; 102(11):362. PubMed ID: 20034251
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.
    Perrin JM; Friedman RA; Knilans TK; ;
    Pediatrics; 2008 Aug; 122(2):451-3. PubMed ID: 18676566
    [No Abstract]   [Full Text] [Related]  

  • 20. Attention-deficit/hyperactivity disorder: are we medicating for social disadvantage? (For).
    Isaacs D
    J Paediatr Child Health; 2006 Sep; 42(9):544-7. PubMed ID: 16925542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.